English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Feline nonflea hypersensitivity dermatitis ( NFHD ) is a frequent cause of over‐grooming, scratching and skin lesions. Multimodal therapy often is necessary.    Hypothesis/Objectives  To investigate the efficacy of ultramicronized palmitoylethanolamide ( PEA ‐um) in maintaining methylprednisolone‐induced remission in  NFHD  cats.    Animals  Fifty‐seven  NFHD  cats with nonseasonal pruritus were enrolled originally, of which 25 completed all study requirements to be eligible for analysis.    Methods and materials  Cats were randomly assigned to  PEA ‐um (15 mg/kg per os, once daily; n = 29) or placebo (n = 28) while receiving a 28 day tapering methylprednisolone course. Cats responding favourably to methylprednisolone were then administered only  PEA ‐um (n = 21) or placebo (n = 23) for another eight weeks, followed by a four week long treatment‐free period. Cats were maintained in the study until relapse or study end, whichever came first. Primary outcome was time to relapse. Secondary outcomes were pruritus Visual Analog Scale (p VAS ),  SCOR ing Feline Allergic Dermatitis scale ( SCORFAD ) and owner Global Assessment Score ( GAS ).    Results  Mean relapse time was 40.5 days (±7.8  SE ) in  PEA ‐um treated cats (n = 13) and 22.2 days (±3.7  SE ) for placebo (n = 12;  P  = 0.04). On Day 28, the severity of pruritus was lower in the  PEA ‐um treated cats compared to placebo ( P  = 0.03). Mean worsening of pruritus at the final study day was lower in the  PEA ‐um group compared to placebo ( P  = 0.04), whereas  SCORFAD  was not different between groups. Mean owner  GAS  at the final study day was better in the  PEA ‐um than the placebo‐treated group ( P  = 0.05).    Conclusion and clinical importance  Ultramicronized palmitoylethanolamide could represent an effective and safe option to delay relapse in  NFHD  cats.

veterinary dermatology

Effect of dietary supplementation with ultramicronized palmitoylethanolamide in maintaining remission in cats with nonflea hypersensitivity dermatitis: a double‐blind, multicentre, randomized, placebo‐controlled study